PubMed Health⌕ Search

Biomedical subjects

N Nedopil

Publications and source records attributed to N Nedopil.

At least 37 records · Page 2Linked to original sources
PubMed1984

Methysergide decreases prolactin release after FK 33-824 [Tyr-D-Ala-Gly-MePhe-Met(o)-ol], a potent analogue of methionine enkephalin. A study in man.

This study investigated the mechanisms which may underly the prolactin (PRL) stimulating effects of FK 33-824, a potent enkephalin analogue. FK 33-824 (1 mg) was infused in healthy volunteers before and after pretreatment with 3 mg methysergide, a serotonin receptor blocker. All subjects showed a release of PRL after FK 33-824, which was significantly diminished after pretreatment with methysergide.

Adult↗
PubMed1984

Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial.

16 patients with paranoid and hallucinatory symptoms, who were concurrently receiving no other medication, participated in a double blind trial. Either 3 mg FK 33-824 or 20 mg diazepam was injected i.m. over a 2-day period, with a subsequent cross-over for the second medication. Both FK 33-824 and diazepam caused a slight decrease in psychopathological symptoms as measured by the BPRS, but no differences could be observed in their effect on schizophrenic symptoms such as hallucinations and delusions.

Adult↗
PubMed1984

Postdexamethasone prolactin and cortisol: a biological state variable in depression.

In 70 inpatients with major depressive disorder postdexamethasone cortisol and prolactin, but not baseline cortisol and prolactin, was found to correlate significantly with various state variables of depression. Postdexamethasone prolactin appeared to be a more specific state variable of depression compared with postdexamethasone cortisol. While prolactin was decreased following dexamethasone in controls and nonendogenous depressed patients, in endogenous depressed patients prolactin was increased by 30%. Due to this inverse prolactin response to dexamethasone, the sensitivity of this test should be considerably increased by using a higher dexamethasone dosage. The DST failed to be a diagnostic marker for any subgroup of depression.

Adult↗
PubMed1984

No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia.

In 23 acute, unmedicated, schizophrenic patients, psychotic behaviour and beta-endorphin serum level were measured before and during four weeks of neuroleptic therapy. Prior to drug treatment, beta-endorphin level of all patients was within the normal range. Neuroleptic therapy induced marked elevations of beta-endorphin in eight subjects; statistical analysis revealed a slight but significant increase for the whole group. This endocrine effect was not correlated with therapeutic efficacy of neuroleptic treatment.

Adult↗
PubMed1983

Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 on depressive symptoms.

Nine patients with endogenous depression have been treated with infusions of the synthetic methionine enkephaline analogue FK 33-824 for two days. Only on the first day acute effects on depressive symptoms could be observed. It cannot be decided if the observed mood alterations on the first treatment day are placebo effects. Depressive patients showed fewer adverse reactions than healthy volunteers. This might be explained by the previously described greater pain tolerance in depressives.

Adult↗
PubMed1983

The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.

The prognosis of a clinical neuroleptic treatment was prospectively examined in 26 schizophrenic patients using a predetermined set of predictors and outcome criteria. Prognosis before treatment did not discriminate significantly between patients with good and poor outcome. Significant differences of outcome were observed between the prognostic groups, if prognosis was established after 5 days of treatment. Retrospective analysis of individual predictors indicated the following rank order: initial improvement, age, duration of symptoms before treatment, sex, subjective tolerance of the treatment. The relative weight of the individual predictor in forming the prognosis is still an open question.

Adult↗
PubMed1983

Detoxification treatment for chronic schizophrenic patients: experimental results and data from a survey.

Blood detoxification as a treatment of schizophrenia has been studied intensively since 1977 by a number of research centers. Results of an open study on 10 chronic schizophrenic patients--two showing improvement--were less favorable than those reported in the initial publications. In order to possibly identify a subgroup of responders to this treatment, a survey was undertaken in which 95 centers were invited to participate. Of the 95 centers which originally treated schizophrenic patients with detoxification and which were asked to send data on these patients to the Registry of the European Dialysis and Transplant Association, 39 centers replied (35 from Europe and four from the United States). From the 100 patients reported on in Europe, 17 were reported to be very much improved and 22 to be improved. Of the patients from the United States, 86% were reported as improved. No subgroup of responders could be identified, and differences between centers concerning nosological subgroups, treatment methods, and results were so great that no real comparison was possible. Although data from this survey are not totally conclusive, in connection with the updated literature they do not encourage further research in this treatment of schizophrenia.

Adult↗
PubMed1982

Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.

A double-blind study of the behavioral effects of short-term naloxone hydrochloride administration was performed in 32 schizophrenic and 26 manic patients in a World Health Organization collaborative project. There was a significant naloxone-associated reduction in overall physician-rated symptoms in schizophrenic patients concurrently treated with neuroleptic medication (N = 19) but not in medication-free schizophrenics (N = 13). Physician rating of auditory hallucinations showed significant naloxone-associated improvement for the total schizophrenic population, while self-ratings of auditory hallucinations showed improvement only in neuroleptic-treated schizophrenics. While further studies are needed to delineate these effects as to clinical significance, they may bear etiological implications for the psychobiology of schizophrenia, including the possibility of synergistic effects of dopamine and endorphin blockade. Naloxone produced no significant behavioral effects in manic patients. These findings are discussed with relationship to the hypotheses of endorphin involvement in schizophrenia and mania.

Adult↗
PubMed1981

Initial improvement as predictor of outcome of neuroleptic treatment.

Improvement of acute psychotic exacerbations under neuroleptic therapy can depend on the time course of the disease itself, on the individual patient or on the specific neuroleptic applied. Previous studies demonstrated that neither the characteristics of the patients nor the disease qualities could predict the outcome of neuroleptic therapy (review by May and Goldberg 1978). In this study the initial improvement after the onset of neuroleptic treatment was tested for its predictive value. In 33 patients treated with constant doses of butyrophenones the decrease of psychotic symptomatology during the first 5 days of treatment not only accounted for the major part of the overall improvement, but was also a relatively reliable predictor for the further course of the therapy.

Adult↗
PubMed1980

Blood purification treatment of schizophrenia.

In order to gather information about the usefulness of blood purification methods as a treatment for chronic schizophrenic patients, "mini-questionnaires" were sent to all European centers working with this method. The questionnaires consisted of two parts, one asking the psychiatrist about the disease itself and the evaluation of treatment, the other one asking the nephrologist about the specific method used. --A preliminary report, based on the evaluation of 53 questionnaires indicated--although far from offering conclusive results--that all schizophrenic patients did not profit equally from the therapy and that patients treated for less than 6 hours per week were not likely to improve. Implications for further research are discussed.

Evaluation Studies as Topic↗